November 15, 2018 10:09 AM EST

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

ENDPOINTS

→ The non-opioid painkiller developer Centrexion, which is led by former Pfizer $PFE chief Jeffrey Kindler, has reportedly postponed its IPO. The Boston-based company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

ENDPOINTS

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Cen­trex­ion de­lays IPO; Ex­elix­is makes $40M as Cabome­tyx wins EU nod

ENDPOINTS

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Centrexion delays IPO; Exelixis makes $40M as Cabometyx wins EU nod

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?